Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Go back to Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)| Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) | Delayed: 2.23 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.23 | 52 Week High | $19.62 | |||
| Open | $2.23 | 52 Week Low | $7.65 | |||
| Day High | $2.23 | P/E | N/A | |||
| Day Low | $2.23 | EPS | $-0.22 | |||
| Volume | 50 | |||||
